# Critical Evaluation of Systemic Immune Profiling Hypotheses in Neurodegeneration
I will systematically evaluate each hypothesis, identifying specific weaknesses, counter-evidence with PubMed citations, alternative explanations, and key falsification experiments.
---
## Hypothesis 1: Circulating hs-CRP as Disease-Modifying Target via Microglial IL-1β Amplification
### Specific Weaknesses in the Evidence
**1. Causality vs. Correlation Problem**
The cited evidence (PMID: 29726919) demonstrates correlation between elevated hs-CRP and cognitive decline but does not establish CRP as a pathogenic driver. hs-CRP is an acute-phase reactant synthesized primarily in hepatocytes in response to IL-6; its elevation may be a downstream consequence of CNS pathology rather than a causal factor.
**2. Species-Specific CRP Biology**
The mechanistic pathway invokes CRP binding to phosphocholine and activating NLRP3 (PMID: 21616951), but this work was conducted with model systems. Human CRP is a pentameric molecule with distinct ligand-binding properties from mouse CRP, which is a monomeric acute-phase protein. These structural differences may invalidate direct translation of murine inflammation data to human therapeutics.
**3. IL-1β-Tau Linkage is Context-Dependent**
While IL-1β drives tau hyperphosphorylation via GSK-3β (PMID: 22306678), this evidence comes from in vitro systems and acute injury models. Chronic, low-grade peripheral inflammation in aging may not recapitulate these acute experimental conditions.
### Counter-Evidence and Contradicting Findings
**Genetic Evidence Against CRP Causality:**
- Mendelian randomization studies have failed to demonstrate that CRP genetic variants influence Alzheimer's disease risk, suggesting CRP elevation is epiphenomenal (PMID: 24336809)
- IL1RN (IL-1 receptor antagonist) polymorphisms, which would modulate IL-1β signaling, do not show consistent association with AD risk in genome-wide studies
**Clinical Trial Contradictions:**
- Canakinumab (anti-IL-1β antibody) trials in cardiovascular disease showed no cognitive benefit despite marked CRP reduction (CANTOS trial)
- Non-steroidal anti-inflammatory drugs (NSAIDs), which reduce peripheral inflammation, failed in AD prevention trials and may even accelerate cognitive decline (PMID: 18641406)
**Alternative Function of CRP:**
- CRP may have protective functions including enhancement of amyloid-β phagocytosis and promotion of debris clearance, complicating therapeutic targeting
### Alternative Explanations
1. **Reverse Causality**: Neurodegeneration causes neuronal stress → microglial activation → IL-6 release → hepatic CRP production. CRP is a biomarker of CNS disease activity, not a driver.
2. **Shared Upstream Driver**: Both elevated CRP and neurodegeneration are consequences of a common cause (e.g., vascular dysfunction, metabolic syndrome, chronic infection).
3. **Inflammation as Adaptive Response**: The inflammatory response may represent beneficial CNS defense that becomes maladaptive only in specific contexts or with aging.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Mendelian randomization using CRP genetic instruments | No causal effect of CRP on AD risk |
| CRP-lowering with statins or canakinumab in MCI | No change in tau PET or CSF p-tau trajectory |
| Conditional CRP expression specifically in liver | No effect on microglial IL-1β or tau pathology |
| Administration of human CRP to CRND8 mice | No acceleration of tau pathology |
### Revised Confidence Score
**0.42** (down from 0.72)
The correlation between hs-CRP and cognitive decline is well-established, but the causal chain—particularly the therapeutic tractability of targeting CRP—is unsupported by genetic evidence and clinical trial data from related anti-inflammatory approaches.
---
## Hypothesis 2: CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege
### Specific Weaknesses in the Evidence
**1. Internal Contradiction in Supporting Evidence**
The hypothesis acknowledges that genetic CCR2 deficiency "alters tau pathology" (PMID: 25034862)—a finding that actually contradicts the therapeutic premise. If CCR2+ monocytes influence tau pathology, their depletion may have unintended consequences on the second major AD proteinopathy.
**2. Heterogeneity of CCR2+ Monocytes**
CCR2+ monocytes constitute a diverse population with context-dependent functions. The hypothesis treats them as uniformly pathogenic, but recruited monocytes may serve both protective (Aβ phagocytosis, debris clearance) and harmful (cytokine release, synaptic pruning) functions depending on disease stage.
**3. Mechanistic Gap: DAM Phenotype Acquisition**
The claim that infiltrating monocytes "adopt DAM-like states" (PMID: 31988279) conflates transcriptional signatures with functional states. DAM signature acquisition does not necessarily equate to neurotoxicity, as DAM in some contexts promote Aβ clearance.
### Counter-Evidence and Contradicting Findings
**Beneficial Functions of CCR2+ Monocytes:**
- CCR2+ monocytes contribute to Aβ clearance in early disease stages; their depletion worsens amyloid pathology in APP/PS1 mice at early timepoints (PMID: 21304891)
- Monocyte-derived macrophages show higher phagocytic capacity for Aβ compared to brain-resident microglia in vitro
**Timing Paradox:**
- The therapeutic window concept lacks human validation. MCI represents a heterogeneous stage where pathology may be too advanced for single-target intervention.
- Aggressive peripheral immunosuppression in AD patients (e.g., natalizumab) has shown neurological worsening, suggesting peripheral immune contribution to CNS homeostasis.
**Species Differences in Monocyte Trafficking:**
- Mouse models show more robust monocyte infiltration across the BBB compared to humans, where the BBB remains largely intact until late disease stages. Human relevance of murine infiltration studies is uncertain.
### Alternative Explanations
1. **Adaptive Response Hypothesis**: CCR2+ monocyte recruitment represents a compensatory attempt to clear amyloid that becomes dysregulated with aging. Inhibition would remove beneficial while reducing harmful functions.
2. **Source of Infiltrating Cells**: The relative contribution of CCR2+ monocyte infiltration versus microglia proliferation to disease-associated states remains controversial, with recent single-cell studies suggesting microglia dominate.
3. **CCL2/CCR2 as Biomarker Rather Than Driver**: CCL2 elevation may reflect microglial activation rather than causing it, serving as a marker of inflammatory burden without therapeutic tractability.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| CCR2 antagonist in 3xTg-AD mice during early pathology | No cognitive benefit or worsening of Aβ pathology |
| Single-cell RNA-seq of human AD brain showing infiltrating monocytes | Predominance of microglia-derived cells over peripheral monocytes |
| Human PET with CCR2 radiotracer showing minimal BBB crossing | Lack of target engagement at therapeutic doses |
### Revised Confidence Score
**0.45** (down from 0.68)
The hypothesis has biological plausibility but is undermined by contradictory evidence regarding the effects of CCR2 modulation on tau pathology and the uncertain translation from mouse models with artificially high monocyte infiltration to human disease.
---
## Hypothesis 3: Fecal Microbiota Transplantation to Reset Microglial Priming States
### Specific Weaknesses in the Evidence
**1. Uncertain Mechanism: HDAC6 in Microglia**
The proposed pathway invokes HDAC6-mediated chromatin remodeling linking gut dysbiosis to microglial phenotypes, but PMID: 28539446 addresses HDAC6 in glial cells generally, not specifically in the gut-brain axis. HDAC6 is primarily cytoplasmic and involved in α-tubulin acetylation and protein aggregation; its role in epigenetic programming is poorly defined.
**2. Germ-Free Mouse Limitations**
Germ-free mice have profoundly abnormal immune systems, making them unreliable models for translating microbiome findings. The absence of microbial colonization leads to hypoplastic Peyer's patches, altered microglial maturation, and abnormal immune responses that may not reflect human physiology.
**3. Human FMT Evidence is Preliminary**
FMT has demonstrated efficacy for *C. difficile* infection and shows promise in metabolic disease, but neurological outcomes from human FMT trials have been disappointing. The referenced evidence (PMID: 30967469) shows FMT transfer *increases* Aβ in germ-free hosts, which could be interpreted as evidence against the therapeutic approach.
### Counter-Evidence and Contradicting Findings
**Clinical Trial Failures:**
- Probiotic trials (Lactobacillus/Bifidobacterium combinations) for cognitive improvement in MCI/AD have shown minimal to no benefit in meta-analyses (PMID: 30675859)
- Antibiotic-induced microbiome perturbation in humans does not consistently alter inflammatory biomarkers or cognitive outcomes
**Microbiome Heterogeneity:**
- Gut microbiome compositions vary dramatically across populations, geographies, and diets. The "healthy donor" profile remains undefined, and different donors produce divergent FMT outcomes.
**LPS as Cause vs. Effect:**
- Elevated serum LPS in AD patients may result from increased intestinal permeability secondary to aging and neurodegeneration rather than causing it (PMID: 25427979 showed elevated sCX3CL1 but this does not establish directionality).
### Alternative Explanations
1. **Epiphenomenal Gut Dysbiosis**: Microbiome changes in AD reflect dietary alterations, medication effects (antibiotics, PPIs, metformin), and physical activity reduction that accompany cognitive decline, rather than driving pathology.
2. **Microbiome as Modulator, Not Initiator**: The gut microbiome may influence disease severity or rate of progression without altering core disease mechanisms. Effects may be too modest to be therapeutically meaningful.
3. **Combination Therapy Requirement**: Microbiome modulation alone may be insufficient; the epigenetic priming described may require additional interventions to reverse once established.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| FMT from young donors to 5xFAD mice | No reduction in amyloid plaques or microglial activation |
| Human FMT trial with 12-month follow-up | No change in CSF inflammatory biomarkers or amyloid PET |
| Germ-free mice colonized with AD-associated microbiome | No acceleration of pathology compared to controls |
### Revised Confidence Score
**0.38** (down from 0.65)
Despite strong preclinical interest, the microbiome-neuroinflammation axis remains mechanistically unclear, and human therapeutic translation has been disappointing. The HDAC6 mechanism is particularly speculative.
---
## Hypothesis 4: CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation
### Specific Weaknesses in the Evidence
**1. Soluble CX3CL1 as "Decoy" is Mechanistically Unclear**
The hypothesis proposes that elevated sCX3CL1 acts as a decoy receptor, but the biology of CX3CL1 is complex. CX3CL1 exists in membrane-bound and soluble forms with potentially distinct signaling outcomes. sCX3CL1 can function as a chemokine attracting CX3CR1+ cells, which may be beneficial for recruiting microglia to pathology.
**2. CX3CR1 Deficiency Shows Mixed Effects**
The cited PMID: 19797663 shows enhanced tau pathology in CX3CR1-deficient mice, but other studies demonstrate CX3CR1 deficiency reduces amyloid pathology and improves cognitive function in different models. The net effect depends on the relative contributions of tau versus amyloid pathology.
**3. Species Differences in CX3CR1 Expression**
CX3CR1 is expressed at much higher levels on mouse microglia than human microglia. Human microglial responses to fractalkine signaling may differ qualitatively from murine responses.
### Counter-Evidence and Contradicting Findings
**Context-Dependent Effects:**
- CX3CR1 deficiency reduces Aβ deposition in APP/PS1 mice (PMID: 22962435) but worsens tau pathology, demonstrating the therapeutic dilemma
- CX3CL1/CX3CR1 signaling has neuroprotective effects in models of excitotoxicity and ischemia; global disruption may remove beneficial pathways
**Alternative Interpretations of sCX3CL1 Elevation:**
- sCX3CL1 elevation may represent a compensatory upregulation attempting to restore neuron-microglia communication in the face of pathology
- The 2.4-fold elevation (PMID: 25427979) may be insufficient to overwhelm membrane-bound signaling
### Alternative Explanations
1. **Compensatory Upregulation**: CX3CL1 and sCX3CL1 elevations represent homeostatic attempts to recruit or activate microglia that become overwhelmed by pathology severity.
2. **Stage-Specific Functions**: CX3CR1 signaling may be beneficial in early disease (promoting surveillance) but maladaptive in late disease (sustaining inappropriate activation). A mimetic peptide could be beneficial early but harmful late.
3. **Receptor Desensitization**: Chronic sCX3CL1 elevation may cause CX3CR1 desensitization, and therapeutic intervention would need to overcome this rather than further increase ligand.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| CX3CR1 agonist in PS19 tauopathy mice | Worsening of tau pathology and cognitive function |
| CX3CL1-Fc fusion in aged 5xFAD mice | No improvement in synaptic density or cognition |
| Measurement of CX3CR1 desensitization in human AD microglia | Chronic receptor uncoupling that mimetic cannot overcome |
### Revised Confidence Score
**0.48** (down from 0.70)
The fractalkine axis has biological plausibility but faces the fundamental challenge of context-dependent effects on different proteinopathies. The therapeutic window is poorly defined, and species differences raise translation concerns.
---
## Hypothesis 5: P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis
### Specific Weaknesses in the Evidence
**1. Clinical P2X7 Antagonist Development Failures**
Multiple P2X7 antagonists have progressed to clinical trials for inflammatory conditions (rheumatoid arthritis, COPD) and failed to demonstrate efficacy. This suggests either our understanding of P2X7 biology is incomplete or that peripheral P2X7 inhibition is insufficient to modulate disease.
**2. ATP as Peripheral Mediator is Unproven**
The hypothesis proposes that peripheral ATP from gut dysbiosis maintains microglial activation, but serum ATP levels (PMID: 31704476) correlate with disease severity without establishing causality. ATP is rapidly degraded in circulation by ectonucleotidases, and its half-life in blood is minutes.
**3. Pyroptosis in Human AD is Uncertain**
Gasdermin D-mediated pyroptosis has been demonstrated in mouse models of neuroinflammation, but direct evidence for this cell death pathway in human AD microglia remains limited.
### Counter-Evidence and Contradicting Findings
**P2X7 Biology Complexities:**
- P2X7 is expressed on multiple cell types including neurons, astrocytes, and peripheral immune cells. Global blockade may disrupt physiological functions including synaptic transmission and ABC transporter function at the BBB.
- P2X7 activation can also promote anti-inflammatory IL-10 release in certain contexts
**Alternative Sources of Microglial IL-1β:**
- The NLRP3 inflammasome in microglia can be activated by Aβ fibrils directly, amyloid plaques, urate crystals, and mitochondrial dysfunction, reducing the relative contribution of ATP-P2X7 signaling.
**Failed Clinical Translation:**
- P2X7 antagonists (e.g., CE-224,535, GSK1482160) showed no efficacy in rheumatoid arthritis and inflammatory bowel disease despite robust preclinical data.
### Alternative Explanations
1. **P2X7 as Modulator, Not Driver**: ATP-P2X7 signaling may fine-tune microglial responses rather than drive pathology fundamentally. Inhibition would reduce but not eliminate inflammatory activation.
2. **Neuronal P2X7 Effects**: P2X7 on neurons can regulate neurotransmitter release and synaptic function; blockade may have neurological effects independent of microglia.
3. **Redundancy with Other Purinergic Receptors**: P2Y12, P2Y6, and other ATP/UTP receptors may compensate for P2X7 inhibition, limiting therapeutic efficacy.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| P2X7 antagonist in 5xFAD mice for 12 months | No change in amyloid load, microglial IL-1β, or cognition |
| Measurement of BBB-penetrant P2X7 antagonist in CSF | Insufficient target engagement in CNS |
| Single-cell RNA-seq of human AD microglia | P2X7 expression does not correlate with inflammatory state |
### Revised Confidence Score
**0.40** (down from 0.63)
Despite a well-characterized receptor-ligand system, clinical translation of P2X7 antagonists has failed in peripheral inflammatory diseases, raising concerns about CNS applications. The peripheral ATP hypothesis is particularly speculative.
---
## Hypothesis 6: STAT3 Epigenetic Priming as Mechanism of Peripheral Cytokine Memory
### Specific Weaknesses in the Evidence
**1. "Trained Immunity" in CNS is Theoretically Predicted**
The concept of trained immunity (long-term epigenetic reprogramming of innate immune cells) is well-established in monocytes/macrophages, but its applicability to brain microglia remains largely theoretical. Microglia are yolk-sac derived and self-renew; whether they undergo analogous training requires direct demonstration.
**2. IL-6 Trans-Signaling Evidence is Extrapolated**
The cited PMID: 15936006 demonstrates IL-6 trans-signaling activates STAT3 in primary microglia, but this is a acute in vitro finding. Sustained IL-6 exposure causing stable epigenetic changes via super-enhancer formation has not been demonstrated in microglia.
**3. HDAC6 is Cytoplasmic, Not Epigenetic**
HDAC6 is primarily a cytoplasmic deacetylase with no known role in transcription factor acetylation or super-enhancer regulation. The mechanism linking HDAC6 inhibition to restored microglial ramification (PMID: 28539446) does not involve the epigenetic pathway proposed in this hypothesis.
**4. BRD4 Evidence is in Macrophages, Not Microglia**
PMID: 24335479 demonstrates BRD4-mediated super-enhancers in LPS-primed macrophages. Whether this mechanism operates in microglia, which are embryologically and functionally distinct, is unproven.
### Counter-Evidence and Contradicting Findings
**IL-6 Has Neuroprotective Functions:**
- IL-6 can activate neuroprotective pathways via STAT3 in neurons (PMID: 12529404)
- IL-6 deficiency worsens outcome in some CNS injury models
**STAT3 Has Complex, Cell-Type-Specific Effects:**
- Microglial STAT3 activation promotes wound healing and debris clearance acutely
- Neuronal STAT3 is critical for axonal regeneration
- Global STAT3 inhibition could disrupt these beneficial functions
**Epigenetic Changes May Be Adaptive:**
- H3K27ac at inflammatory gene promoters may represent appropriate transcriptional responses to pathology rather than maladaptive priming.
### Alternative Explanations
1. **STAT3 as Secondary Marker**: IL-6/STAT3 activation may be a consequence of pathology that does not itself cause disease progression. CSF IL-6 predicts MCI conversion (PMID: 25533297) but this may reflect disease severity rather than driving it.
2. **Therapeutic Target Toxicity**: WP1066 and similar STAT3 inhibitors are associated with significant off-target effects and toxicity that limit clinical development.
3. **Bystander Effect**: STAT3 activation in microglia may reflect environmental signals without causing autonomous functional changes.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| ATAC-seq of microglia from IL-6-treated vs. control mice | No durable chromatin accessibility changes |
| H3K27ac ChIP-seq comparing young vs. old mouse microglia | Age-related changes are not accelerated by IL-6 |
| STAT3 inhibitor in aged 5xFAD mice | No prevention or reversal of trained immunity phenotype |
### Revised Confidence Score
**0.32** (down from 0.58)
This hypothesis extends the trained immunity concept to microglia without direct evidence and invokes HDAC6 in an epigenetic context where it does not function. The mechanistic chain is the weakest of all seven hypotheses.
---
## Hypothesis 7: Anti-CD47/SIRPα Checkpoint Therapy to Enhance Phagocytic Clearance
### Specific Weaknesses in the Evidence
**1. Safety Concerns with Anti-CD47 Therapy**
Anti-CD47 antibodies cause dose-limiting anemia in primates due to interaction with CD47 on erythrocytes. While magrolimab uses subclinical doses with intermittent scheduling, this significantly limits therapeutic utility and raises questions about CNS penetration at effective doses.
**2. ARIA-H Risk Paradox**
The hypothesis proposes that anti-CD47 would reduce ARIA-H (microhemorrhage) risk by promoting "orderly phagocytosis," but CD47-SIRPα blockade by definition enhances phagocytosis of any CD47-expressing cell. This would include erythrocytes and potentially promote cerebral amyloid angiopathy (CAA)-related microhemorrhages.
**3. Context-Dependent "Don't Eat Me" Signals**
CD47 is upregulated on neurons as a protective response to injury. Suppressing CD47-SIRPα signaling could lead to inappropriate phagocytosis of viable neurons, particularly in the absence of clear discrimination between healthy and damaged cells.
### Counter-Evidence and Contradicting Findings
**CD47 Expression Changes May Be Adaptive:**
- Neuronal CD47 upregulation in response to TNF-α (PMID: 29030481) may represent a neuroprotective attempt to prevent phagocytic elimination of stressed neurons.
**Synaptic Pruning Requirements:**
- CD47 is required for appropriate developmental synaptic pruning; its blockade during development causes synaptic dysfunction. Adult application may have different but not necessarily beneficial effects.
**Combination Therapy Complexity:**
- Anti-Aβ antibodies (lecanemab, donanemab) achieve plaque clearance despite amyloid opsonization by other mechanisms. Adding anti-CD47 may not synergize but rather compete for microglial engagement.
**Human Translation Concerns:**
- SIRPα polymorphisms associated with AD risk in Asian populations (PMID: 29445967) may indicate the receptor has complex biology beyond simple activation/inhibition.
### Alternative Explanations
1. **Microglial Dysfunction is Downstream**: The underlying causes of impaired microglial phagocytosis in AD (inflammaging, metabolic dysfunction, aging) would persist despite checkpoint blockade, limiting efficacy.
2. **Timing Is Everything**: Anti-CD47 might only be beneficial during a narrow therapeutic window before synaptic loss becomes irreversible. Identification of this window in humans is impractical.
3. **Off-Target Phagocytosis**: Enhanced macrophage activity may promote peripheral inflammation and cytokine release that counteracts CNS benefits.
### Key Experiments That Could Falsify the Hypothesis
| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Anti-CD47 in aged 5xFAD mice with established plaques | No additional plaque reduction beyond anti-Aβ alone |
| Safety assessment: increased CAA and microhemorrhages | ARIA-H rate higher than with anti-Aβ monotherapy |
| Biomarker: increased neuronal injury markers (NfL) | Microglial over-activation causing neuronal death |
### Revised Confidence Score
**0.52** (down from 0.71)
Despite reasonable mechanistic plausibility and preclinical data, the safety profile of anti-CD47 therapy in primates raises significant concerns for clinical development in a chronic neurodegenerative indication. The ARIA paradox deserves particular scrutiny.
---
## Summary of Revised Confidence Scores
| # | Hypothesis | Original | Revised | Primary Concern |
|---|-----------|----------|---------|-----------------|
| 1 | hs-CRP → Microglial IL-1β | 0.72 | **0.42** | Causality not established; failed anti-inflammatory trials |
| 2 | CCR2+ Monocyte Depletion | 0.68 | **0.45** | Internal contradiction regarding tau; timing paradox |
| 3 | FMT for Microglial Reprogramming | 0.65 | **0.38** | Failed probiotic trials; HDAC6 mechanism unsupported |
| 4 | CX3CL1 Mimetic Peptide | 0.70 | **0.48** | Context-dependent effects on Aβ vs. tau |
| 5 | P2X7 Antagonism | 0.63 | **0.40** | Clinical P2X7 antagonist failures |
| 6 | STAT3 Epigenetic Priming | 0.58 | **0.32** | CNS trained immunity theoretical; HDAC6 misuse |
| 7 | Anti-CD47 Checkpoint Therapy | 0.71 | **0.52** | Safety concerns; ARIA-H paradox |
---
## Overarching Methodological Concerns
### 1. Mouse-to-Human Translation Gap
All hypotheses rely substantially on mouse model data. However, murine neuroinflammation differs from human disease in critical aspects:
- Microglial density and distribution
- BBB permeability and immune cell trafficking
- Aging as a predominant risk factor (mouse models use young animals)
- Proteinopathy timing and progression
### 2. Single-Biomarker Focus
Most hypotheses target a single peripheral immune marker. Human neurodegenerative diseases likely involve multiple concurrent inflammatory processes, suggesting single-target approaches may be insufficient.
### 3. Therapeutic Window Assumptions
The "early intervention" premise assumes pathology is not yet established at MCI. However, amyloid and tau pathology typically begin 10-20 years before clinical symptoms, suggesting MCI already represents a late stage.
### 4. Failed Precedent
Large clinical trials targeting neuroinflammation (enoxaparin, naproxen, rofecoxib, tarenflurbil) have consistently failed to demonstrate benefit or shown harm. The hypotheses presented do not adequately address why their approach would succeed where others have failed.
### 5. Biomarker Validation
Many proposed biomarkers (sCX3CL1, serum ATP, LPS activity) have not been rigorously validated as surrogate endpoints or demonstrated to predict therapeutic response in human trials.